{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:05Z","timestamp":1786118945208,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Third-generation cephalosporins and fluoroquinolones are particularly prone to promoting bacterial resistance. Their use in Emergency Departments (EDs) is poorly known. Our objectives were to assess the use of antibacterial agents in French EDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study is a retrospective study of antibiotics delivered to the adult units of 11 EDs of French academic centres in 2012, and to six of these EDs between 2009 and 2012.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The total antibiotic use was 66.4 defined daily doses (DDD)\/1000 ED visits in 2012, and it increased between 2009 and 2012 (yearly estimate, +1.8\u00b10.9 DDD\/1000 ED visits,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.048). The 3GC-FQ class, which grouped third-generation cephalosporins and fluoroquinolones, accounted for 39.2% of the total antibiotic use, and the use of this class of antibiotics was highly variable among EDs (range, 31.6\u201349.5% of total antibiotic use). The aminopenicillin and \u03b2-lactamase inhibitor\/3GC-FQ ratio varied among EDs [median (range), 0.91 (0.52\u20131.25)]. Between 2009 and 2012, there was a significant decrease in the use of the 3GC-FQ class (yearly estimate, \u22120.8\u00b10.4% of total antibiotic use), antipneumococcal fluoroquinolones (\u22120.8\u00b10.3%) and other fluoroquinolones (\u22120.9%\u00b10.3%), and there was a significant increase in the use of third-generation cephalosporins (+0.7\u00b10.3%), aminoglycosides (+0.4\u00b10.1%), imidazole derivatives (+0.4\u00b10.1%) and lincosamides (+0.1\u00b10.0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Fluoroquinolones and third-generation cephalosporins are widely used in the ED. Their use is highly variable among EDs. Third-generation cephalosporins were increasingly used between 2009 and 2012, whereas the use of fluoroquinolones decreased. Reduced use of cephalosporins in the ED, without increasing fluoroquinolone use, should be aimed at through antibiotic stewardship programs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mej.0000000000000331","type":"journal-article","created":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T11:32:28Z","timestamp":1443699148000},"page":"189-195","source":"Crossref","is-referenced-by-count":1,"title":["Use of broad-spectrum antibiotics in French EDs: different trends for third-generation cephalosporins and fluoroquinolones"],"prefix":"10.1097","volume":"24","author":[{"given":"Eric","family":"Batard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Vibet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathelle","family":"Lemarchand","sequence":"additional","affiliation":[{"name":"Emergency Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Navas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Lepelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Potel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Montassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 4","key":"R1-20230916","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/382690","article-title":"\u201cCollateral damage\u201d from cephalosporin or quinolone antibiotic therapy","volume":"38","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R2-20230916","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1128\/CMR.00023-13","article-title":"Trends in human fecal carriage of extended-spectrum beta-lactamases in the community: toward the globalization of CTX-M","volume":"26","author":"Woerther","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1553-2712.2009.00353.x","article-title":"National trends in emergency department antibiotic prescribing for elders with urinary tract infection, 1996\u20132005","volume":"16","author":"Caterino","year":"2009","journal-title":"Acad Emerg Med"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1553-2712.2012.01342.x","article-title":"National study of antibiotic use in emergency department visits for pneumonia, 1993 through 2008","volume":"19","author":"Neuman","year":"2012","journal-title":"Acad Emerg Med"},{"key":"R5-20230916","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1128\/AAC.02039-13","article-title":"Antibiotic utilization for acute respiratory tract infections in U.S. emergency departments","volume":"58","author":"Donnelly","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-20230916","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10096-014-2049-3","article-title":"Increasing use of third-generation cephalosporins for pneumonia in the emergency department: may some prescriptions be avoided?","volume":"33","author":"Goffinet","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R7-20230916","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/emermed-2014-204067","article-title":"Implementation of an intensified antibiotic stewardship programme targeting third-generation cephalosporin and fluoroquinolone use in an emergency medicine department","volume":"32","author":"Borde","year":"2015","journal-title":"Emerg Med J"},{"key":"R8-20230916","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/MEJ.0000000000000124","article-title":"Use of fluoroquinolones and third-generation cephalosporins in the emergency department: an 11-year survey","volume":"21","author":"Montassier","year":"2014","journal-title":"Eur J Emerg Med"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/infdis\/166.3.542","article-title":"Meningococcal disease and influenza-like syndrome: a new approach to an old question","volume":"166","author":"Hubert","year":"1992","journal-title":"J Infect Dis"},{"key":"R11-20230916","first-page":"20130519","article-title":"Assessing pneumococcal meningitis association with viral respiratory infections and antibiotics: insights from statistical and mathematical models","volume":"280","author":"Opatowski","year":"2013","journal-title":"Proc Biol Sci"},{"key":"R12-20230916","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jac\/dkq525","article-title":"Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community","volume":"66","author":"Vernaz","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R13-20230916","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2125.2011.04161.x","article-title":"The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings","volume":"74","author":"Aldeyab","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"R14-20230916","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/jac\/dkn534","article-title":"The impact of antimicrobial drug consumption and alcohol-based hand rub use on the emergence and spread of extended-spectrum beta-lactamase-producing strains: a time-series analysis","volume":"63","author":"Kaier","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R15-20230916","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijantimicag.2005.08.016","article-title":"Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991\u20132003 at a university hospital in Taiwan","volume":"26","author":"Hsueh","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1128\/AAC.01076-09","article-title":"Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals","volume":"54","author":"Hsu","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/archinte.168.17.1897","article-title":"Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli","volume":"168","author":"Rodr\u00edguez-Ba\u00f1o","year":"2008","journal-title":"Arch Intern Med"},{"key":"R18-20230916","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/jac\/dkl035","article-title":"Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases","volume":"57","author":"Calbo","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R19-20230916","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10096-003-1084-2","article-title":"Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients","volume":"23","author":"Colodner","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R20-20230916","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ajic.2005.03.009","article-title":"Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon","volume":"33","author":"Kanafani","year":"2005","journal-title":"Am J Infect Control"},{"key":"R21-20230916","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/jac\/dkt212","article-title":"Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change?","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"R22-20230916","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1136\/thx.2009.121434","article-title":"BTS guidelines for the management of community acquired pneumonia in adults: update 2009","volume":"64","author":"Lim","year":"2009","journal-title":"Thorax"},{"key":"R23-20230916","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10096-014-2264-y","article-title":"Escherichia coli antibiotic resistance in emergency departments. Do local resistance rates matter?","volume":"34","author":"Grignon","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R24-20230916","doi-asserted-by":"crossref","DOI":"10.1007\/s15010-015-0793-7","article-title":"High variability among Emergency Departments in 3rd-generation cephalosporins and fluoroquinolones use for community-acquired pneumonia","author":"Batard","year":"2015","journal-title":"Infection"},{"key":"R25-20230916","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1465-9921-14-44","article-title":"Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH","volume":"14","author":"Blasi","year":"2013","journal-title":"Respir Res"},{"key":"R26-20230916","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5694\/j.1326-5377.1998.tb138964.x","article-title":"Should third-generation cephalosporins be the empirical treatment of choice for severe community-acquired pneumonia in adults?","volume":"168","author":"Paterson","year":"1998","journal-title":"Med J Aust"},{"key":"R27-20230916","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1089\/mdr.2014.0064","article-title":"Poor compliance with community-acquired pneumonia antibiotic guidelines in a large Australian private hospital emergency department","volume":"20","author":"Robinson","year":"2014","journal-title":"Microb Drug Resist"},{"key":"R28-20230916","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/intqhc\/mzq077","article-title":"A quality improvement initiative to improve adherence to national guidelines for empiric management of community-acquired pneumonia in emergency departments","volume":"23","author":"McIntosh","year":"2011","journal-title":"Int J Qual Health Care"}],"container-title":["European Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00063110-201706000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:11:00Z","timestamp":1786036260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00063110-201706000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mej.0000000000000331","relation":{},"ISSN":["0969-9546"],"issn-type":[{"value":"0969-9546","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}